WO2008152405A3 - Cible anti-cancer - Google Patents

Cible anti-cancer Download PDF

Info

Publication number
WO2008152405A3
WO2008152405A3 PCT/GB2008/002050 GB2008002050W WO2008152405A3 WO 2008152405 A3 WO2008152405 A3 WO 2008152405A3 GB 2008002050 W GB2008002050 W GB 2008002050W WO 2008152405 A3 WO2008152405 A3 WO 2008152405A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
vdac
treatment
well
protein complexes
Prior art date
Application number
PCT/GB2008/002050
Other languages
English (en)
Other versions
WO2008152405A2 (fr
Inventor
Dean Fennell
Nyree Crawford
Alex Chacko
Patrick Johnston
Original Assignee
Univ Belfast
Dean Fennell
Nyree Crawford
Alex Chacko
Patrick Johnston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0711602A external-priority patent/GB0711602D0/en
Priority claimed from GBGB0718790.9A external-priority patent/GB0718790D0/en
Application filed by Univ Belfast, Dean Fennell, Nyree Crawford, Alex Chacko, Patrick Johnston filed Critical Univ Belfast
Publication of WO2008152405A2 publication Critical patent/WO2008152405A2/fr
Publication of WO2008152405A3 publication Critical patent/WO2008152405A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la détermination d'un complexe entre un peptide BH3 et un peptide VDAC et l'utilisation de ce complexe comme cible pour l'identification de nouveaux médicaments et de nouveaux traitements.
PCT/GB2008/002050 2007-06-15 2008-06-16 Cible anti-cancer WO2008152405A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0711602.3 2007-06-15
GB0711602A GB0711602D0 (en) 2007-06-15 2007-06-15 Anti-cancer target
GBGB0718790.9A GB0718790D0 (en) 2007-09-26 2007-09-26 Anti-cancer target
GB0718790.9 2007-09-26

Publications (2)

Publication Number Publication Date
WO2008152405A2 WO2008152405A2 (fr) 2008-12-18
WO2008152405A3 true WO2008152405A3 (fr) 2009-04-09

Family

ID=39884899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002050 WO2008152405A2 (fr) 2007-06-15 2008-06-16 Cible anti-cancer

Country Status (1)

Country Link
WO (1) WO2008152405A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
EP3047276B1 (fr) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Procédé de profilage de bh3
WO2016176299A1 (fr) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
JP2022523771A (ja) * 2019-02-26 2022-04-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016787A1 (fr) * 1997-09-26 1999-04-08 Washington University Agonistes de mort cellulaire
WO2004022580A2 (fr) * 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Peptides bh3 et leur methode d'utilisation
WO2005007878A2 (fr) * 2003-07-22 2005-01-27 Dana-Farber Cancer Institute, Inc. Procede pour moduler l'apoptose et composition associees

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016787A1 (fr) * 1997-09-26 1999-04-08 Washington University Agonistes de mort cellulaire
WO2004022580A2 (fr) * 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Peptides bh3 et leur methode d'utilisation
WO2005007878A2 (fr) * 2003-07-22 2005-01-27 Dana-Farber Cancer Institute, Inc. Procede pour moduler l'apoptose et composition associees

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHACKO A ET AL.: "BH3 domain of BID interacts with VDAC1/Prohibitin complex and depolarizes mitochondria in the absence of cristae remodelling", ABSTRACT BOOK, 26 October 2007 (2007-10-26), & 15TH ECDO EUROCONFERENCE ON APOPTOSIS; PORTOROZ; SLOVENIA; OCTOBER 26-31, 2007, pages P-64, XP002502902, Retrieved from the Internet <URL:http://www.ecdo.eu/portoroz/textfiles_PDF/Complete_1110_with%20extra%20posters.pdf> *
GAJKOWSKA B ET AL: "A novel embedment-free immunoelectron microscopy technique reveals association of apoptosis-regulating proteins with subcellular structures.", HISTOCHEMICAL JOURNAL, vol. 34, no. 8-9, August 2002 (2002-08-01), pages 441 - 446, XP002502901, ISSN: 0018-2214 *
ROSTOVTSEVA T K ET AL: "Bid, but not Bax, regulates VDAC channels", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 14, 2 April 2004 (2004-04-02), pages 13575 - 13583, XP002502900, ISSN: 0021-9258 *
SHIMIZU S ET AL: "Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 152, no. 2, 22 January 2001 (2001-01-22), pages 237 - 250, XP002168868, ISSN: 0021-9525 *
SHIMIZU S ET AL: "Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 577 - 582, XP002502903, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2008152405A2 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2006081826A3 (fr) Vaccin a base de peptide de survivine
WO2007009894A3 (fr) Nouveaux peptides utilises dans le traitement de l&#39;obesite
WO2008087186A3 (fr) Nouveaux peptides pour le traitement de l&#39;obésité
CA2818990C (fr) Proteines de repetition concues se liant a l&#39;albumine serique
PH12014501083A1 (en) Anticancer fusion protein
WO2008152405A3 (fr) Cible anti-cancer
WO2006103666A3 (fr) Polypeptides bid isoles, polynucleotides les codant et anticorps diriges contre ces polypeptides, methodes d&#39;utilisation pour induire l&#39;arret du cycle cellulaire ou l&#39;apoptose
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
WO2008087188A3 (fr) Nouveaux peptides pour le traitement de l&#39;obésité
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l&#39;obesite
NZ603200A (en) Peptides and their use
EP2264048A4 (fr) Peptide agoniste des-[asp1]-[ala1],angiotensin-(1-7) et composes pharmaceutiques pour le traitement de maladies
WO2006048452A3 (fr) Nouveaux peptides utiles dans le traitement de l&#39;obesite
MX2013006213A (es) Proteina de funsion anticancer.
WO2014057484A8 (fr) Peptides pour le traitement de maladies neurodégénératives
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2012014214A3 (fr) Peptides dérivés de l&#39;inhibiteur 1 de l&#39;activateur du plasminogène (pai‑1) pour le traitement de l&#39;hypertension
MX2013007872A (es) Proteina de fusion anticancer.
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2020103961A3 (fr) Peptide de ciblage de tumeurs cérébrales et application associée
WO2008087189A3 (fr) Nouveaux peptides pour le traitement de l&#39;obésité
WO2011123858A3 (fr) Peptides ccn3 à visée thérapeutique et leurs analogues
WO2012143477A3 (fr) Protéine hybride anticancéreuse
WO2015043566A8 (fr) Peptides cycliques se liant aux bêta-amyloïdes et leur utilisation
WO2007113837A3 (fr) Variants de vdac n-terminal et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775754

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775754

Country of ref document: EP

Kind code of ref document: A2